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Serial biochemical studies were performed in 12 patients
treated with intracoronary streptokinase infusionfor acute
myocardial infarction, in order to study the method of
activation of the fibrinolytic system during local admin-
istration of a relatively low dose of this drug and to
determine correlations between systemic effects and re-
perfusion. Plasma samples were obtained before and
every 15 minutes during the infusion of streptokinase
and after completion of the therapy. Streptokinase dos-
age in this study was 211,000 :t 88,000 IV (:t SO). The
average time from the onset of symptoms to the start of
infusion was 2 hours 50 minutes (range 1 hour 10 minutes
to 3 hours 30 minutes). Reperfusion occurred in six pa-
tients and temporary recanalization in three; in three
patients no recanalization was achieved.
Fibrinolytic assays of pretreatment plasma samples
revealed elevated levels of plasminogen activators, pre-
sumably caused by the release of tissue-type plasminogen
activator after a condition of stress. Plasminogen con-
centrations decreased from 94 :t 17% to 44 :t 30%.
Alphaz-antiplasmin fell from 84 :t 27% to 12 :t 19%;
in seven patients no plasmin inhibitor activity was mea-
surable at the completion of the infusion. Free plasmin
Since the introduction of streptokinase in 1933 by Tillett
and Garner (I), numerous trials have been undertaken to
treat various thromboembolic disorders, including myo-
cardial infarction, with this drug. Dosage schedules, routes
of administration and infusion procedures vary greatly in
the published studies, and this has led to contradictory re-
sults. The dosage schedules are generally based on in vitro
studies from the late 1950s (2) and on diverging theories
From *St. Antonius Hospital, Nieuwegein, tTNO Gaubius Institute
for Cardiovascular Research, Leiden, and tDiaconessen Hospital, Heernst-
ede, The Netherlands. Dr. Brommer was supported by Praeventiefonds.
The Hague Grant 28-813.
Manuscript received January 6, 1986;revised manuscript received July
29, 1986, accepted August 20, 1986.
Address for reprints: J .A. Six, MD, Department of Cardiology. St.
Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein. The Netherlands.
<D 1987 by the American College of Cardiology
occurred in samples only when this inhibitor had dis-
appeared. This resulted in a lytic state leading to deg-
radation of fibrinogen, the levels of which fell from 2.9
± 0.7% to 1.5 ± 1.1%. Fibrinogen degradation prod-
ucts, measured in plasma with monoclonal antibodies,
increased exponentially during streptokinase infusion in
at least four patients.
Despite the small number of study patients involved,
systemic fibrinolysis, defined as fibrinogen decrease to
below 2.0 g/liter, and recanalization appeared to be de-
pendent on each other (chi-square = 7.1, P < 0.01). It
may be inferred that systemic fibrinolysis after intra-
coronary administration of streptokinase promotes re-
canalization of occluded arteries, although this does not
seem to be a prerequisite. It cannot be concluded from
these data whether enhancement of intracoronary clot
lysisby systemic effects is caused by free plasmin formed
in the circulation or by endogenous thrombolysis made
possible by the disappearance of the main inhibitor of
fibrinolysis, alphayantiplasmin, or by the high local con-
centration of free streptokinase.
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about the mechanism of fibrinolytic activation by strepto-
kinase (3).
At least three theories exist. The first implies that strep-
tokinase can diffuse into thrombi, where it can form com-
plexes with fibrin-bound or penetrating plasminogen, which
in turn would activate other plasminogen molecules to the
proteolytic enzyme plasmin and lead to lysis (4,5). Ac-
cording to a second theory, complexes of streptokinase and
plasminogen formed in the blood would penetrate the throm-
bus, where they would activate fibrin-bound plasminogen
(6). A third theory assumes the formation of plasmin from
circulating plasminogen at the surface of the thrombus re-
sulting in lysis (7,8). A fourth theory should be mentioned,
namely, that systemic activation of fibrinolysis neutralizes
fibrinolytic inhibitors so that plasmin, activated by endog-
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enous plasminogen activators within the thrombus, gets the
opportunity to lyse the thrombus from the inside (9).
Although these hypotheses are not mutually exclusive,
they have led to greatly differing opinions about what an
optimal dosage schedule of streptokinase should be. Ideally
it would have a high efficacy and a low risk of bleeding
complications. According to the first theory, a high con-
centration of streptokinase exclusively in the vicinity of the
thrombus should produce the best results. The second hy-
pothesis, however, would favor a high concentration of
streptokinase in the blood, in order to capture practically
all circulating plasminogen in a complex with streptokinase
without leaving residual plasminogen for conversion to plas-
min. The last two alternatives suggest that an intermediate
dose should be given, one just high enough to neutralize
circulating antiplasmins but leave some plasminogen in the
circulation. In the treatment of acute myocardial infarction
in particular, differences in the success rate of intracoronary
and intravenous administration of streptokinase might be
due to different doses of the agent rather than the route of
administration.
A second problem in establishing dosage schedules is
the inter-individual variation in the reaction to streptokinase,
measured as systemic fibrinogen breakdown or generation
of fibrinogen degradation products. This variability is gen-
erally ascribed to different levels of circulating streptoki-
nase-neutralizing antibodies that occur after streptococcal
infections (10-12). To our knowledge, systematic investi-
gations of the influence of such antibodies on the clinical
effect of streptokinase, demonstrated by immunologic tech-
niques such as those described by Moran et al. (13), have
not been performed.
The aim of this study was to obtain support for one of
the proposed dosage schemes by examining the process of
systemic fibrinolysis introduced by relatively small amounts
of streptokinase that are infused during intracoronary throm-
bolysis in the treatment of acute myocardial infarction. We
tried to correlate systemic changes induced by intracoronary
streptokinase with recanalization of occluded coronary ar-
teries.
Methods
Study patients. Intracoronary thrombolysis with strep-
tokinase was performed in 12 patients with acute myocardial
infarction. Inclusion criteria were I) prolonged chest pain
during more than 30 minutes provided that it started less
than 3 hours before admission to the hospital and was unre-
lieved by nitroglycerin; and 2) persistent ST segment ele-
vation with associated reciprocal depression in opposite leads.
Patients with anamnestic hemorrhagic or thrombotic dis-
orders were excluded. Informed consent was obtained from
all patients or from close family members.
Streptokinase infusion. Selective coronary angiography
was performed using the Judkins approach (14). Infusion
of 250,000 IU of streptokinase (Streptase, Behring Pharma),
dissolved in 500 ml saline solution, was administered into
the coronary artery at a rate of 2,000 to 4,000 IU/min.
Heparin was administered routinely in a single dose of 5 ,000
to 10,000 IU after introduction of the catheter into the fem-
oral artery. No corticosteroids were given.
Every 15 minutes, for up to 60 minutes or after the
appearance of rhythm disturbances, coronary angiography
of the previously occluded artery was performed. After re-
perfusion had been observed, the infusion was continued
for 15 minutes and then was stopped. When no reperfusion
was achieved, treatment was stopped after 250,000 or 350,000
IU of streptokinase had been infused.
Blood samples. Blood samples were collected before
and 15,30,45 and 60 minutes after the start of thrombolytic
therapy. From some patients blood samples were also ob-
tained 3, 12 and 24 hours after treatment. The first and the
last blood samples were collected by venipuncture in the
arm, with minimal venous congestion to avoid release of
tissue-type plasminogen activator (t-PA). All other samples
were withdrawn through the intracardiac catheter after rins-
ing it with saline solution and after discarding the first milli-
liters of blood. Specimens were collected in plastic tubes
containing 0.1 vol sodium citrate, 0.11 M, and placed im-
mediately in icewater and centrifuged at 4°C. Plasma sam-
ples were snap frozen at - 20cC and kept below - 40°C
until use.
Blood assays. Assays included determination of fibrin-
ogen by the Clauss method (15). The fibrinolytic activity
of euglobulin fractions with the addition of Ci-inacrivator
was measured on plasminogen-rich fibrin plates (16); plas-
minogen was assayed in vitro after its conversion to plasmin
by streptokinase using chromogenic substrate S-2251 (Kabi)
as described by Friberger et al. (17). Values were corrected
for amidolytic activity of the plasma occurring sponta-
neously before the addition of streptokinase to the test tube.
Alpha--antiplasmin was measured as described previously
(18). Recently, new quantitative enzyme immunoassays for
the determination of several types of degradation products
of either fibrinogen or fibrin have been developed. One of
these tests was carried out on the pretreatment samples to
determine the concentration of degradation products of fi-
brinogen only. In this test, two different monoclonal anti-
bodies were used: a "catching" antibody directed against
a neoantigen on fragment E not cross-reacting with intact
fibrinogen and a "tagging" antibody against fragment E
still containing fibrinopeptide A (19). The reaction was car-
ried out in microtiter plates (lmulon, Dynatech) and read in
a Titertek Multiscan (Flow Laboratories) (41).
The fibrinolytic activity is expressed as follows: for de-
terminations on fibrin plates, the surface area is expressed
in square millimeters of lysed zones; for the chromogenic
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substrate method, it is expressed as a percent of the value
measured in pooled plasma obtained from at least 18 healthy
members of the laboratory personnel; the spontaneous lytic
activity is expressed as arbitrary units: increase in optical
density per minute (~OD x 1,000 x min I).
Statistics. The mean and range of values are mentioned
because of the nonparametric distribution of most values.
The graphically represented standard deviations of fibrin-
olytic activities were calculated after logarithmic transfor-
mation of the values in square millimeters. The appearance
of free plasmin as an indicator of successful therapy was
analyzed statistically using a chi-square test. Where normal
values are mentioned, 95% confidence limits are meant.
Results
Coronary reperfusion. Twelve male patients were in-
cluded in our study whose mean age was 59.7 years (range
49 to 75). Complete obstruction was seen in the flow area
of the left anteriordescending coronary artery (fivepatients),
the left circumflex coronary artery (three patients) and the
right coronary artery (four patients). The averagedelay from
the beginning of chest pain to the start of the intracoronary
infusion was 2 hours, 50 minutes (range I hour, 10 minutes
to 3 hours, 30 minutes); the in-hospital delay was about 50
minutes (range 45 to 60). In six cases recanalization of the
occluded coronary artery was achieved, in three a temporary
reperfusion was observed and in three other cases there was
a permanent occlusion that was resistant to the fibrinolytic
therapy.
There were no bleeding complications in our patients,
apart from hematoma at the arterial puncture site. No patient
died from arrhythmia and no adverse reactions to the drug
were observed.
Fibrinolytic studies (Table 1). The results offibrinolytic
studies are summarized in Table J. In the acute stage of
myocardial infarction, fibrinolytic activity of euglobulin
fractions before the administration of streptokinase varied
from 0 to 333 mm? (normal range in patients at rest is 13
to 70 mrn"). Immediately after the administration of strep-
tokinase, the fibrinolytic activity increased in all but one
patient, in whom a rise of fibrinolytic activity was delayed.
Mean values for all patients are represented in Figure I.
Amidolytic activity of plasma toward the substrate H-D-
VAL-LEU-LYS-pNA was found before therapy in only one
patient. This patient showed signs compatible with intra-
vascular coagulation: fibrinogen degradation products were
present (Fig. 2, Patient E) and alpha--antiplasmin was low.
In seven patients, high values of amidolytic activity were
generated during therapy.
Plasminogen concentrations decreased during the infu-
sion in all patients. Before therapy the average plasminogen
concentration was 94% (range 57 to I 19%; normal 70 to
128%). It decreased to an average of 44%, (range 9 to 71%).
The nadir was reached on completion of the infusion of
streptokinase. After 24 hours the mean value increased to
73% (range 48 to 85%).
Alpha eantiplasmin values on admission were within nor-
mal limits in all patients (mean 89%), except in the patient
mentioned earlier with signs of intravascular coagulation,
in whom a value of 24% was found. In 7 of the 12 patients,
alphayantiplasmin appeared to be completely consumed
during the thrombolytic therapy (Fig. 3). The regeneration
of alpha--antiplasmin was measured after completion of
therapy in six patients; the average concentration in these
Table l. Data on Fibrinolytic Variables Measured Directly Before and After Streptokinase Administration
Arnidolytic
Fibrinolytic Activity (tlOD Alpha,-
Activity x 1.000 x Plasminogen antiplasmin Fibrinogen
(rnm') mIn ') (%) (%) (g/literj FDP (MimI)
Total SK
Case Recanalization (X I,OOOIUj Before After Before After Before After Before After Before After Before Maximal
y 160 19 418 1.8 18.0 97 41 78 0 2.3 0.4 < 0.5 70
2 N 350 0 183 2.0 15 101 78 65 13 2.9 2.6 < 0.5 < 0.5
3 Y 240 I 260 1.5 31.5 57 12 62 0 3.1 I.2 < 0.5 37
4 T 240 62 183 1.3 1.7 89 68 86 49 3.2 2.8 < 0.5 < 0.5
5 Y 240 310 602 7.5 61.0 66 4 24 0 1.9 0.1 544 134
6 T 350 83 257 0.9 29.6 101 9 126 28 3.0 0.1 < 0.5 150
7 Y 240 nd nd 1.6 nd 106 nd 104 nd 3.9 3.1 < 0.5 2
8 N 60 I 277 1.6 2.2 97 68 90 0 2.7 2.7 < 0.5 16
9 T 90 333 254 1.1 10.2 104 38 74 0 4.2 I.2 nd nd
10 y 150 I 589 1.2 20.3 100 33 88 0 2.8 0.5 < 0.5 < 0.5
11 Y 200 0 122 1.0 1.5 119 98 95 45 1.8 1.7 nd nd
12 N 220 76 488 1.1 5.8 89 40 113 0 2.6 2.2 < 0.5 87
FOP = fibrinogen degradation products; N = no recanalization; nd = not determined; SK = streptokinase; T = transients; Y = angiographically
proved recanalization.
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10 Figure 2. Fibrinogen degradation products measured before and
during streptokinase infusion in five patients (A to E).
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Figure 1. Mean fibrinolytic activity (expressed as lysis area in
mrrr') of euglobulin fractions of plasma samples with addition of
Ci-inactivator before and during intracoronary streptokinase
administration. Mean and standard deviations (vertical bars) have
been calculated after logarithmic transformation. Dotted lines rep-
resent 95% confidence limits of normal values.
patients increased after the end of therapy from 23% (range
oto 48%) to 72% (range 39 to 90%) 12 hours later.
Fibrinogen concentrations before therapy varied from
1.9 to 3.7 glliter (normal 2.0 to 4.0 g/liter). During strep-
tokinase therapy the fibrinogen level decreased in all pa-
tients. The lowest concentration of fibrinogen observed was
Figure 3. Alphayantiplasmin values expressed as per-
cent activity of pooled plasma in 12 individual patients,
showing complete disappearance in 7 patients during
streptokinase administration. Patients showing reper-
fusion (solid lines) and patients showing no reperfusion
(dashed lines).
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0.1 g/Iiter with the Clauss method. On admission, fibrinogen
degradation products were demonstrable with specific
monoclonal antibodies in only I of 10 patients tested. The
concentrations of fibrinogen degradation products did not
increase to the same extent in all patients during strepto-
kinase infusion. A gradual increase in degradation products
was observed in Patients I, 3, 8 and 12, represented by an
almost straight line in a semi logarithmic plot (Fig. 2).
Discussion
Local (intracoronary) streptokinase administration is now
widely used during a brief period in the acute phase of
myocardial infarction. The dosage used, 2,000 to 4,000
IU/min, is arbitrarily chosen and not necessarily optimally
effective. One question that needs to be answered is whether
that dosage of streptokinase, which induces the most ex-
tensive systemic fibrinolysis, results in the highest per-
centage of recanalization of occluded coronary arteries. We
studied systemic fibrinolysis by detailed biochemical anal-
ysis of plasma samples taken at regular intervals during
intracoronary streptokinase therapy.
Pretreatment fibrinolytic activity. The pretreatment
plasma samples of some patients showed abnormally high
values of spontaneous fibrinolytic activity. Because this ac-
tivity is mainly determined by tissue-type plasminogen ac-
tivator, as can be concluded from its resistance to inhibition
by Cj-inactivator (16), it may be inferred that it is due to
high concentrations of activator, presumably released by
endothelial cells under conditions of stress (20). In only one
patient (Fig. 2, Patient E) was this accompanied by elevated
levels of fibrinogen degradation products.
Systemic effects of intracoronary streptokinase. In
most cases, systemic effects of thrombolytic therapy became
apparent, as can be deduced from the increase of fibrinolytic
activity and amidolytic activity, the generation of fibrinogen
degradaton products and the decrease of plasminogen, alpha2-
antiplasmin and fibrinogen levels. Streptokinase will form
a complex with circulating plasminogen. This complex ac-
tivates any remaining plasminogen in the blood to the pro-
teolytic enzyme plasmin, which will be neutralized partly
by alphayantiplasmin. Indeed, alpha--antiplasmin levels de-
creased with increasing doses of streptokinase (Fig. 3).
Only when alpha--antiplasmin (and other inhibitors such
as alphas-macroglobulin) are largely consumed will free
plasmin occur in the blood, where it may attack not only
circulating proteins, for example fibrinogen, but also the
fibrin matrix of a thrombus. Spontaneous lytic activity of
plasma, detected with S-225 I in our study, originates vir-
tually only from plasmin and from streptokinase-plasmin-
ogen complex. Figure 4 shows that this lytic activity occurs
only when the concentration of alpha-antiplasmin is very
low. This is a strong argument for the theory that this activity
is due to free plasmin. Indeed, in plasma samples with high
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Figure 4. Alpha-antiplasmin and spontaneous amidolytic activ-
ity, measured in the same plasma sample. Spontaneous lytic ac-
tivity is due to free circulating plasmin, which occurs only in the
absence of antiplasmin.
lytic activity, a low fibrinogen and a high level of fibrinogen
degradation products were found (Fig. 5 and 6).
It is difficult to accurately measure the unaffected, clot-
table fibrinogen in plasma containing degradation products,
because some of these degradation products interfere with
polymerization of fibrin monomers. They will interfere with
functional clotting tests such as the Clauss method. Other
degradation products, such as circulating fragment X, are
incorporated in the clot and will influence gravimetric mea-
surements. Nevertheless, Clauss's method, although it
produces low values, has proved useful in the monitoring
of thrombolytic therapy.
Fibrinogen degradaton products and lytic activity. It
was surprising to find that fibrinogen degradation products
appeared after the first few thousand units of streptokinase,
even before the disappearance of alpha--antiplasrnin from
the circulating blood. This early generation of degradation
products can be explained by local exhaustion of the inhib-
itor and degradation of fibrinogen at the site of infusion. As
soon as alpha--antiplasmin is depleted and free plasmin is
detectable in the systemic circulation, degradation products
increase dramatically. A poor but significant correlation was
found between spontaneous lytic activity and the level of
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Figure 5. Percent fibrinogen decrease during streptokinase infu-
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fibrinogen degradation products in those plasma samples
with detectable amounts of split products (Fig. 6).
Systemic fibrinolysis versus coronary recanalization.
Of our 12 patients, 9 showed (temporary) reperfusion; in 7
this was associated with overt systemic fibrinolysis . On the
other hand, three of five patients with slight systemic effects
showed no recanalization. Despite the small number of study
patients, systemic fibrinolysis (defined as fibrinogen de-
crease to less than 2.0 g/liter) and recanalization do not
seem to be independent of each other (chi-square = 7. I,
P < 0.0 I). It may be inferred that systemic fibrinolysis after
intracoronary administration of streptokinase promotes re-
canalization of occluded arteries, although this does not
appear to be an absolute prerequisite. It cannot be concluded
from our data whether enhancement of intracoronary clot
lysis by systemic effects is due to free plasmin formed in
the circulation or to endogenous thrombolysis made possible
by the disappearance of the main inhibitor of fibrinolysis,
alphayantiplasrnin, or to the high local concentration of free
streptokinase.
Previous studies . Several investigators (21-29) have
observed systemic effects after completion of streptokinase
therapy even when administered by local intracoronary in-
fusion. The development of a systemic fibrinolytic state
during intracoronary streptokinase infusion has also been
observed by others (30-32) . Cowley et al. (28) investigated
the systemic effects of intracoronary streptokinase and com-
pared their results with those of Rentrop et al. (33) and
Reduto et al. (34). They defined a " lytic state" as a 70%
Figure 6. Fibrinogen degradation products and spontaneous lytic
activity. measured in the same plasma samples (r = 0.44. P <
0.05).
reduction of fibrinogen concentration using a functional as-
say (Clauss's method [15]). This lytic state occurred in 88%
of their patients who were treated comparably with ours,
but they did not suggest a correlation between this bio-
chemical effect and reperfusion. Their results were con-
cordant with those of White et al. (35). who used the same
laboratory methods (which are mainly useful for screening
purposes) in patients treated according to a protocol similar
to ours. In contrast, Rothbard et al. (32). measuring fibrin-
ogen concentrations by the method of Ratnoff and Menzie
(36). showed a strong association between reperfusion and
the development of a lytic state, which is in agreement with
our results.
In this study we have extended the preceding experience
by analyzing in detail the fibrinolytic state in plasma samples
taken frequently during streptokinase administration. We
were surprised to observe significant systemic effects and,
in some cases, complete disappearance of alphayantiplas-
min within 15 minutes, that is, after the infusion of only
30,000 IU streptokinase (Fig. 3). In addition to the fact that
all patients showed a decrease in alphayanriplasmin , these
observations cast doubt on the generally accepted presence
of streptokinase-neutralizing antibodies in human blood,
which, according to Duckert et al. (21) and Amery et al.
(8), have a level corresponding with more than 250,000 IU
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streptokinase in 95%of patients, or even more than 2,000,000
IU as stated by Moran et al. (II).
Conclusions. It is not necessary to administer a loading
dose of streptokinase to overcome the presumed inhibition
of streptokinase by autologous plasma constituents. The
usual dosage of streptokinase in intracoronary thrombolysis
is sufficient to produce systemic effects in the majority of
patients. Instead of giving higher doses, as seems to be
widely done (37-40), early coronary recanalization might
be promoted by administeringa relatively low dose of strep-
tokinase intravenously soon after admission, while diag-
nostic angiography is being prepared.
We thank Mrs. M.M. Barrett-Bergshoeff and Mrs. E. Hoegee, Gaubius
Institute for technical assistance.
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